MBrace Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$85M

MBrace Therapeutics is a biopharmaceutical company developing a lead antibody-drug conjugate (ADC) candidate, MBRC-101, targeting the EphA5 receptor tyrosine kinase present in various cancers, with the recent completion of an $85 million Series B financing round.